Skip to content
OpenCapital
Get started

Pacific Biosciences of California PACB Short-term restricted cash

Other financials

Income statement

See full
Revenue$37.2M+0.1%
Gross profit$12.8M+1,037%
Operating income-$8.4M+98.1%
Net income-$8.3M+98.1%
EPS (diluted)-$0.03+97.9%

Balance sheet

See full
Cash & equivalents$57.9M-4.7%
Total debt$59.3M+12.1%
Total equity$2.4M-97.4%
Total assets$782.4M-9.1%

Cash flow

See full
Operating cash flow-$44.7M-1.4%
CapEx$3.0M+119%
Free cash flow-$47.7M-5.0%

Valuation

See full
Market cap$496.96M+30.4%
Enterprise value$498.38M+33.5%
P/S3.1×+0.6×

Profitability

See full
Gross margin37.5%+21.3pp
Operating margin-83.3%-38.2pp
Net margin-80.3%-36.1pp
FCF margin-72.6%-20.0pp

Returns & leverage

See full
Return on equity-273.6%+314pp
Debt / equity25.1×+24.5×
Current ratio5.7×-1.0×

Where this comes from

Reported directly by Pacific Biosciences of California in its filing.

Tagged under the XBRL concept pacb:ShortTermRestrictedCashFairValueDisclosure.

The official record: Pacific Biosciences of California’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacific Biosciences of California's short-term restricted cash.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pacific Biosciences of California's short-term restricted cash?
Pacific Biosciences of California (PACB) reported short-term restricted cash of $19K in Q1 2026.
How has Pacific Biosciences of California's short-term restricted cash changed year-over-year?
Pacific Biosciences of California's short-term restricted cash decreased by 97.2% year-over-year, from $690K to $19K.
What is the long-term trend for Pacific Biosciences of California's short-term restricted cash?
Over 4 years (2020 to 2025), Pacific Biosciences of California's short-term restricted cash has grown at a -60.7% compound annual growth rate (CAGR), from $836K to $20K.